Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer

Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer

Source: 
Pharmaceutical Business Review
snippet: 

Takeda Pharmaceutical has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its investigational drug mobocertinib (TAK-788) to treat patients with metastatic non-small cell lung cancer (NSCLC).